FADS2 and acute myeloid leukemia: Imetelstat, a first-in class telomerase inhibitor with clinical efficacy in hematological myeloid malignancies [172], induces ferroptosis in AML through fatty acid desaturase 2 (FADS2)-dependent lipid metabolic pathways [173].